vs
AdvanSix Inc.（ASIX）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.7倍（$359.9M vs $207.3M），AdvanSix Inc.净利率更高（-0.8% vs -62.0%，领先61.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 9.4%），AdvanSix Inc.自由现金流更多（$36.1M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 3.4%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ASIX vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $207.3M |
| 净利润 | $-2.8M | $-128.6M |
| 毛利率 | 7.6% | — |
| 营业利润率 | -0.7% | -54.7% |
| 净利率 | -0.8% | -62.0% |
| 营收同比 | 9.4% | 25.9% |
| 净利润同比 | -892.9% | 3.5% |
| 每股收益（稀释后） | $-0.11 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $359.9M | $207.3M | ||
| Q3 25 | $374.5M | $159.9M | ||
| Q2 25 | $410.0M | $166.5M | ||
| Q1 25 | $377.8M | $139.3M | ||
| Q4 24 | $329.1M | $164.6M | ||
| Q3 24 | $398.2M | $139.5M | ||
| Q2 24 | $453.5M | $147.0M | ||
| Q1 24 | $336.8M | $108.8M |
| Q4 25 | $-2.8M | $-128.6M | ||
| Q3 25 | $-2.6M | $-180.4M | ||
| Q2 25 | $31.4M | $-115.0M | ||
| Q1 25 | $23.3M | $-151.1M | ||
| Q4 24 | $352.0K | $-133.2M | ||
| Q3 24 | $22.3M | $-133.5M | ||
| Q2 24 | $38.9M | $-131.6M | ||
| Q1 24 | $-17.4M | $-170.7M |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | -0.7% | -54.7% | ||
| Q3 25 | -0.9% | -106.9% | ||
| Q2 25 | 7.7% | -64.8% | ||
| Q1 25 | 7.7% | -102.6% | ||
| Q4 24 | -3.9% | -74.3% | ||
| Q3 24 | 7.5% | -94.6% | ||
| Q2 24 | 11.5% | -79.1% | ||
| Q1 24 | -7.0% | -151.9% |
| Q4 25 | -0.8% | -62.0% | ||
| Q3 25 | -0.7% | -112.8% | ||
| Q2 25 | 7.7% | -69.0% | ||
| Q1 25 | 6.2% | -108.5% | ||
| Q4 24 | 0.1% | -80.9% | ||
| Q3 24 | 5.6% | -95.7% | ||
| Q2 24 | 8.6% | -89.5% | ||
| Q1 24 | -5.2% | -156.8% |
| Q4 25 | $-0.11 | $-1.28 | ||
| Q3 25 | $-0.10 | $-1.81 | ||
| Q2 25 | $1.15 | $-1.17 | ||
| Q1 25 | $0.86 | $-1.57 | ||
| Q4 24 | $0.02 | $-1.34 | ||
| Q3 24 | $0.82 | $-1.40 | ||
| Q2 24 | $1.43 | $-1.52 | ||
| Q1 24 | $-0.65 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $815.2M | $-80.0M |
| 总资产 | $1.7B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $19.8M | $421.0M | ||
| Q3 25 | $23.7M | $202.5M | ||
| Q2 25 | $18.4M | $176.3M | ||
| Q1 25 | $8.3M | $127.1M | ||
| Q4 24 | $19.6M | $174.0M | ||
| Q3 24 | $17.3M | $150.6M | ||
| Q2 24 | $12.1M | $480.7M | ||
| Q1 24 | $20.6M | $112.3M |
| Q4 25 | $815.2M | $-80.0M | ||
| Q3 25 | $818.2M | $9.2M | ||
| Q2 25 | $823.7M | $151.3M | ||
| Q1 25 | $794.4M | $144.2M | ||
| Q4 24 | $774.6M | $255.0M | ||
| Q3 24 | $766.4M | $346.8M | ||
| Q2 24 | $746.6M | $432.4M | ||
| Q1 24 | $713.2M | $140.3M |
| Q4 25 | $1.7B | $1.5B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.5B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | 10.0% | -48.6% |
| 资本支出强度资本支出/营收 | 7.7% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $6.4M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $63.7M | $-99.8M | ||
| Q3 25 | $26.6M | $-91.4M | ||
| Q2 25 | $21.1M | $-108.3M | ||
| Q1 25 | $11.4M | $-166.5M | ||
| Q4 24 | $64.2M | $-79.3M | ||
| Q3 24 | $57.3M | $-67.0M | ||
| Q2 24 | $50.2M | $-77.0M | ||
| Q1 24 | $-36.2M | $-190.7M |
| Q4 25 | $36.1M | $-100.8M | ||
| Q3 25 | $66.0K | $-92.7M | ||
| Q2 25 | $-7.2M | $-110.7M | ||
| Q1 25 | $-22.6M | $-167.8M | ||
| Q4 24 | $29.8M | $-79.5M | ||
| Q3 24 | $26.8M | $-68.6M | ||
| Q2 24 | $16.7M | $-79.0M | ||
| Q1 24 | $-71.6M | $-193.9M |
| Q4 25 | 10.0% | -48.6% | ||
| Q3 25 | 0.0% | -58.0% | ||
| Q2 25 | -1.7% | -66.5% | ||
| Q1 25 | -6.0% | -120.5% | ||
| Q4 24 | 9.1% | -48.3% | ||
| Q3 24 | 6.7% | -49.2% | ||
| Q2 24 | 3.7% | -53.7% | ||
| Q1 24 | -21.3% | -178.2% |
| Q4 25 | 7.7% | 0.5% | ||
| Q3 25 | 7.1% | 0.8% | ||
| Q2 25 | 6.9% | 1.5% | ||
| Q1 25 | 9.0% | 1.0% | ||
| Q4 24 | 10.4% | 0.1% | ||
| Q3 24 | 7.7% | 1.2% | ||
| Q2 24 | 7.4% | 1.4% | ||
| Q1 24 | 10.5% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
